病毒性肝炎树鼩动物模型研究与建模策略

病毒性肝炎是由肝炎病毒引起的肝脏疾病。在我国,病毒性肝炎高度流行,其中又以乙型肝炎病毒(Hepatitis B virus,HBV)和丙型肝炎病毒(Hepatitis C virus,HCV)危害较大。动物模型是研究疾病感染与发病机制,进行药物与疫苗研究的必要工具。目前病毒性肝炎实验动物模型的研究已取得长足的发展,主要集中于病毒在动物体内的感染特性及发病规律方面。本文仅就病毒性肝炎动物模型,尤其乙型、丙型肝炎树鼩动物模型的研究及建模策略进行综述。     

抗HCV药物筛选系统研究进展

丙型肝炎病毒(Hepatitis C virus,HCV)感染的持久性引发慢性肝病疾病,并可能发展成为肝硬化和肝癌。目前对HCV的治疗不能达到理想的治疗效果,所以开发新型抗HCV药物迫在眉睫。抗HCV药物筛选的细胞模型,如复制子系统、假病毒系统、细胞培养系统,动物模型,如黑猩猩、uPA-SCID小鼠等,取得了快速的进展,并推动丙型肝炎的研究和抗HCV药物的发现。     

树鼩驯养繁殖实验动物标准及丙型肝炎动物模型技术平台建设的探讨

目前用于生物医学研究的树鼩大多数来源于野生捕获,由于个体间的差异较大,其实验结果的均匀性和可重复性较差,亟待解决树鼩人工饲养设施条件、繁殖关键技术、动物质量标准等一系列基础科学问题。许多文献报道了树鼩与其他实验动物比较,在肝病研究中具有巨大的开发应用潜力,在丙型肝炎动物模型研究中,亟待解决丙型肝炎病毒(HCV)细胞培养体系、HCV病毒感染剂量与感染途径、HCV病毒对树鼩体外、体内感染后病毒核酸检测、抗体检测和病理检测等技术方法的建立及动物模型评价标准问题。本文就上述问题系统性地进行初步报道,旨在为树鼩早日实现实验动物化和丙型肝炎疾病研究中应用提供科学依据。     

诊断丙型肝炎的第二代酶标试剂简介

<正>丙型肝炎是世界性流行疾病,危害很大,中老年患病率较高,正常人群中平均0.3％抗—HCV阳性。主要以接触、输液方式传播,在输液性肝炎中,90％以上是丙型肝炎。丙型肝炎感染后,潜伏期为2—26周不等,急性丙型肝炎临床症状较轻,重症丙型肝炎较为少见,但发展成慢性肝炎的比例较大,并可发展成肝硬化和肝癌。过去对丙型肝炎的诊断主要采用     

丙肝病毒非灵长类同源病毒的研究进展

丙型肝炎病毒(Hepatitis C virus,HCV)是一种危害人类健康的病原体,感染人体后极易导致慢性肝炎,并能引起肝纤维化或脂肪肝,可能进一步发展成为肝硬化、肝癌等终末期肝病。尽管已被发现20多年,丙肝病毒的来源以及进化途径一直没有确定。与此同时,缺乏合适的动物模型严重阻碍HCV致病机理的研究。从2011年起,随着新型测序技术的应用,多种丙肝非灵长类同源病毒相继被发现,这些研究成果将在研究丙肝病毒来源、进化途径以及相关动物模型建立中起重要作用。     

丙肝病毒非灵长类同源病毒的研究进展北大核心CSCD

丙型肝炎病毒(Hepatitis C virus,HCV)是一种危害人类健康的病原体,感染人体后极易导致慢性肝炎,并能引起肝纤维化或脂肪肝,可能进一步发展成为肝硬化、肝癌等终末期肝病。尽管已被发现20多年,丙肝病毒的来源以及进化途径一直没有确定。与此同时,缺乏合适的动物模型严重阻碍HCV致病机理的研究。从2011年起,随着新型测序技术的应用,多种丙肝非灵长类同源病毒相继被发现,这些研究成果将在研究丙肝病毒来源、进化途径以及相关动物模型建立中起重要作用。     

丙型肝炎病毒治疗药物与耐药基因突变

丙型肝炎病毒（Hepatitis C virus,HCV）引起的慢性丙型肝炎全球广泛流行,严重影响人类健康,药物治疗是防控该疾病的唯一有效途径。在干扰素-利巴韦林联合疗法在丙型肝炎治疗方面获得较好成效的基础上,直接抗病毒药物（Direct-acting antiviral,DAA）尤其泛基因型靶向药物的使用,使病毒持续性应答率（Sustained virologic response,SVR）超过95%。靶向药物直接作用于病毒增殖的关键蛋白,大大提高病毒清除率,然而由于病毒基因变异产生耐药性成为治愈丙型肝炎的最大障碍。本综述围绕HCV流行与危害、现有丙型肝炎治疗药物、直接靶向抗病毒药物,从病毒多样性与耐药基因突变特征的角度,全面介绍丙型肝炎抗病毒治疗靶向药物与耐药发生。     

磷酯酰肌醇-4-磷酸与丙肝病毒相互关系的研究进展

丙型肝炎由丙肝病毒(hepatitis C virus,HCV)引起,流行性很强。HCV主要通过毒品注射、输血或器官移植传播;极少数情况下,HCV通过血透析、母婴垂直传染。少部分感染HCV的患者会产生急性丙型肝炎,而大多数人会转变成慢性肝炎,其中1/3的人群病情逐渐恶化,严重时导致肝癌。除了肝脏病变,HCV感染还会引起其他组织和器官的损害。因此,对于HCV感染机制的研究显得尤为重要。近年来,寻找参与HCV复制的关键性宿主因子已成为研究热点,磷酯酰肌醇-4-磷酸(phosphatidylinositol-4-phosphate,PI4P)就是其中之一。该文将着重介绍PI4P及相关蛋白参与HCV生命周期的研究进展,并简要总结相关的鞘脂和胆固醇的生理功能。     

丙型肝炎病毒感染与肝细胞癌相关关系的研究进展

世界上有数亿的人口患有丙型肝炎,而丙型肝炎病毒（HCV）的感染易转为慢性,引起肝细胞炎性坏死及再生,导致肝纤维化、硬化甚至肝细胞癌（HCC）,是危害人类健康的一个重要卫生问题。HCV的感染可导致HCC的发生,但HCV相关性HCC的发生机制尚不清楚。免疫逃避机制是感染慢性化的一个重要原因,病毒通过其基因组编码的蛋白使肝细胞发生转化,可能是肝细胞癌变的重要机制。     

丙型肝炎病毒感染与肝细胞癌相关关系的研究进展

世界上有数亿的人口患有丙型肝炎,而丙型肝炎病毒(HCV)的感染易转为慢性,引起肝细胞炎性坏死及再生,导致肝纤维化、硬化甚至肝细胞癌(HCC),是危害人类健康的一个重要卫生问题。HCV的感染可导致HCC的发生,但HCV相关性HCC的发生机制尚不清楚。免疫逃避机制是感染慢性化的一个重要原因,病毒通过其基因组编码的蛋白使肝细胞发生转化,可能是肝细胞癌变的重要机制。     

Design and evaluation of novel tetracyclic benzofurans as palm site allosteric inhibitors of HCV NS5B polymerase

Hepatitis C virus (HCV) NS5B polymerase is a prime target for the development of direct-acting antiviral drugs for the treatment of chronic HCV infection. Several novel and potent HCV NS5B non-nucleoside inhibitors with unique tetracyclic bezonfuran-based structures were prepared and evaluated. Similar to clinical developmental compound MK-8876, N-linked (compounds 1 and 2) and C-linked (compounds 3 and 4) tetracyclic structures maintained broad spectrum anti-replicon potency profiles and demonstrated moderate to excellent oral bioavailability and pharmacokinetic parameters across the three preclinical animal species. To better understand the importance of tetracyclic structures related to pan genotypic potency profiles especially against clinically relevant GT1a variants, the teracycles with different ring size were prepared and in vitro evaluations suggested compounds with six number ring have better overall potency profiles.     

Synthesis and inhibitory activity on hepatitis C virus RNA replication of 4-(1,1,1,3,3,3-hexafluoro-2-hydroxy-2-propyl)aniline analogs

Using our recently developed assay system for full-genome-length hepatitis C virus (HCV) RNA replication in human hepatoma-derived Li23 cells (ORL8), we identified 4-(1,1,1,3,3,3-hexafluoro-2-hydroxy-2-propyl)aniline analog 1a as a novel HCV inhibitor. Structural modifications of 1a provided a series of sulfonamides 7 with much more potent HCV RNA replication-inhibitory activity than ribavirin. Compound 7a showed an additive anti-HCV effect in combination with standard anti-HCV therapy (IFN-α plus ribavirin). Since 7a generated reactive oxygen species (ROS) in the ORL8 system and its anti-HCV activity was blocked by vitamin E, its anti-HCV activity may be mediated at least in part by ROS.     

Synthesis and anti-HCV activity of 3′,4′-oxetane nucleosides

Hepatitis C virus afflicts approximately 180 million people worldwide and currently there are no direct acting antiviral agents available to treat this disease. Our first generation nucleoside HCV inhibitor, RG7128 has already established proof-of-concept in the clinic and is currently in phase IIb clinical trials. As part of our continuing efforts to discover novel anti-HCV agents, 3′,4′-oxetane cytidine and adenosine nucleosides were prepared as inhibitors of HCV RNA replication. These nucleosides were shown not to be inhibitors of HCV as determined in a whole cell subgenomic replicon assay. However, 2′-mono/diflouro analogs, 4, 5, and 6 were readily phosphorylated to their monophosphate metabolites by deoxycytidine kinase and their triphosphate derivatives were shown to be inhibitors of HCV NS5B polymerase in vitro. Lack of anti-HCV activity in the replicon assay may be due to the inability of the monophosphates to be converted to their corresponding diphosphates.     

Synthesis and in vitro antiviral activities of 3′-fluoro (or chloro) and 2′,3′-difluoro 2′,3′-dideoxynucleoside analogs against hepatitis B and C viruses

Chronic infections with hepatitis B virus (HBV) and hepatitis C virus (HCV) lead to serious liver diseases worldwide. Co-infection with HBV and HCV is very common and is associated with increased risk of liver pathogenesis, liver cancer, and liver failure. Several 5-substituted 3′-fluoro (or chloro) (1–4, 6, 7, 17–19) and 2′,3′-difluoro 2′,3′-dideoxynucleosides (15 and 16) were synthesized and evaluated for in vitro antiviral activities against duck hepatitis B virus (DHBV), human hepatitis B virus, and hepatitis C virus. Of these compounds 4, 7, 17, and 19 demonstrated moderate anti-HBV activity, and 2, 4, 7, 8, and 19 were weak inhibitors of HCV. Although 5-iodo derivative (7) was most inhibitory against HCV, it exhibited a reduction in cellular RNA levels in Huh-7 cells. The 5-hydroxymethyl-3′-fluoro-2′,3′-dideoxyuridine (4) and 1-(3-chloro-2,3-dideoxy-β-d-erythro-pentofuranosyl)-5-fluorouracil (19) provided the most inhibition of both viruses without cytotoxicity.     

Tellimagrandin I,HCV invasion inhibitor from Rosae Rugosae Flos

By use of the model virus, expressing the HCV envelope proteins E1 and E2, bioassay guided separation of the MeOH extract from Rosa rugosa Thunb. disclosed tellimagrandin I (1) together with eugeniin (2) and casuarictin (3) as the potent HCV invasion inhibitors. Furthermore, structure–activity relationship analysis of some relative tannins including the synthesized analogs elucidated the partial structures crucial for potent activity of 1.     

Novel 5-arylthio-5H-chromenopyridines as a new class of anti-fibrotic agents

Liver fibrosis is a critical wound healing response to chronic liver injury such as hepatitis C virus (HCV) infection. If persistent, liver fibrosis can lead to cirrhosis and hepatocellular carcinoma (HCC). The development of new therapies for preventing liver fibrosis and its progression to cancer associated with HCV infection remains a critical challenge. Identification of novel anti-fibrotic compounds will provide opportunities for innovative therapeutic intervention of HCV-mediated liver fibrosis. We designed and synthesized a focused set of 5-arylthio-5H-chromenopyridines as a new class of anti-fibrotic agents. Liver fibrosis assays demonstrated that the compounds 3a and 3c show inhibitory activity towards human hepatic stellate cells (LX2) activation at 10 μM. The HCV NS3 and NS5A proteins in HCV subgenome-expressing cells were also significantly reduced in cells treated with 3a and 3c, suggesting the possible inhibitory role of the compounds in HCV translation/replication activities. We have also examined the reactivity of these compounds with medicinally-relevant metal compounds such as platinum and gold. The reactivity of these complexes with metals and during Mass Spectrometry suggests that CS bond cleavage is relatively facile.     

Performance of the automated COBAS AMPLICOR™ system for the detection of hepatitis C virus RNA

Background: The COBAS AMPLICOR^™ (CA) instrument for the amplification and detection steps of the AMPLICOR^™ molecular diagnostic assays has recently been introduced. The system contains a single thermal cycler with two independently controlled heating/cooling blocks, a pipettor, a magnetic particle washer, a photometer and an incubator.Objective: The performance of the CA instrument was evaluated in a routine diagnostic laboratory for the detection of hepatitis C virus (HCV) RNA. The new system was compared with the corresponding microwell plate assay (AMPLICOR HCV Test).Study design: Routine clinical sera (350) from hemodialysis patients and patients with chronic HCV infection and interferon therapy were studied. If discrepant results were obtained, both assays were repeated (specimen preparation, amplification and detection); in addition, the HCV copy number was determined with the AMPLICOR HCV MONITOR^™ Test.Results: There was a correlation between the CA HCV Test and the AMPLICOR HCV Test in 341 of 350 specimens (97%). After resolution of 9 discrepant results, the CA HCV Test gave a sensitivity of 97.8% and a specificity of 99.4%. The most common reason for discrepant results was a low HCV RNA copy number.Conclusion: The CA system was found to be a labor-saving, fast and reliable instrument for the amplification and detection steps of a RT-PCR molecular assay for detection of HCV RNA.     

Hepatitis G virus (GBV-C) infection among Brazilian patients with chronic liver disease and blood donors

Background: The recently discovered hepatitis G virus (HGV) belongs, as hepatitis C virus (HCV), to the Flaviviridae family. HGV has been isolated from the serum of patients with non A-E hepatitis. However, the association of HGV with hepatitis is uncertain.Objective: To determine the HGV prevalence in blood donors and in patients with liver disease and to evaluate a possible correlation between HGV infection and liver disease.Study design: Sera from a total of 113 consecutive patients with chronic liver disease were submitted to a series of liver enzymes and function tests and analyzed for the presence of HBsAg, anti-HBs, anti-HBc, anti-HCV, HCV RNA and HGV RNA. Prevalence of HGV RNA was determined in a group of 87 blood donors.Results: Nine (10%) sera from blood donors and 15 (13%) sera from patients with chronic liver disease were HGV RNA positive. Some 28 (25%) patients were HCV RNA positive, with genotypes 1a, 1b and 3 present in 10, 12 and 5 patients, respectively. A total of 20 (18%) patients were HBsAg carriers. Five (4%) patients were double infected (one with HBV+HCV, one with HBV+HGV and three with HCV+HGV).Conclusion: The proportion (10%) of HGV-infected blood donors was very high when compared with other countries. The results did not allow to establish HGV as an etiologic agent for chronic liver disease. The parenteral route was the presumed means of HGV transmission for only one-third of the patients.     

丙型肝炎病毒感染实验动物模型的研究进展

丙型肝炎病毒（HCV）感染是导致人类慢性病毒性肝炎、肝硬化和肝癌的最主要病因之一。由于缺乏合适的HCV感染实验动物模型,使得针对HCV感染更为有效的疗法及疫苗的研发滞后。黑猩猩是HCV感染研究的最佳实验动物,但由于其来源有限、价格昂贵及临床症状等诸多问题,其应用受限,因此发展新的实验动物模型用于HCV感染相关的基础和应用研究迫在眉睫。近年来,以啮齿类等动物为替代模型取得了不少进展,应用转基因等实验技术使替代动物感染了HCV,并成功应用于多个学科领域的研究。本文分析了HCV自然感染的实验动物、自然感染和非自然感染的替代实验动物在致病机制研究、药物评价和疫苗研发应用中的优缺点及未来研究趋势。     

Potent bisimidazole-based HCV NS5A inhibitors bearing annulated tricyclic motifs

This Letter describes the synthesis and biological evaluation of a number of functionalized bisimidazoles bearing annulated tricyclic motifs as potent inhibitors of HCV NS5A protein. Compound 4h, which contains a substituted tricyclic 6-6-6 xanthene, demonstrated broad genotypic spectrum, compelling potency, and good oral bioavailability with dose-dependent drug exposure level in multiple animal species.